Research programme: Anticancer therapeutics - Ildong Pharmaceuticals

Drug Profile

Research programme: Anticancer therapeutics - Ildong Pharmaceuticals

Alternative Names: ID 6201; ID 6302

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Ildong Pharmaceutical
  • Class Sulfonylureas
  • Mechanism of Action Heat-shock protein inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Oct 2015 Preclinical trials in Cancer in South Korea (unspecified route)
  • 19 Oct 2015 Ildong Pharmaceuticals has patent protection for anticancer drugs in Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top